LP6 Stock Overview
Researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Livzon Pharmaceutical Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.30 |
| 52 Week High | CN¥3.82 |
| 52 Week Low | CN¥2.58 |
| Beta | 0.24 |
| 1 Month Change | 4.43% |
| 3 Month Change | -6.25% |
| 1 Year Change | 18.71% |
| 3 Year Change | 3.77% |
| 5 Year Change | 5.77% |
| Change since IPO | 117.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| LP6 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.9% | 1.7% | 0.3% |
| 1Y | 18.7% | -16.2% | 8.4% |
Return vs Industry: LP6 exceeded the German Pharmaceuticals industry which returned -16.2% over the past year.
Return vs Market: LP6 exceeded the German Market which returned 8.4% over the past year.
Price Volatility
| LP6 volatility | |
|---|---|
| LP6 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LP6 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LP6's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 8,920 | Yanggang Tang | www.livzon.com.cn |
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precocious puberty; and Urofollitropin for injection to treat anovulation and sufferers. It also provides Perospirone hydrochloride tablets to treat schizophrenia; Shenqi Fuzheng Injection to treat weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for treating lung and stomach cancer; anti-viral granules used for clearing heat, eliminating dampness, cooling blood, and detoxifying to treat upper respiratory tract infection and influenza; Tocilizumab injection to treat rheumatoid arthritis; and Recombinant SARSCoV-2 fusion protein vaccine used to prevent diseases caused by SARS-CoV-2 infection.
Livzon Pharmaceutical Group Inc. Fundamentals Summary
| LP6 fundamental statistics | |
|---|---|
| Market cap | €4.07b |
| Earnings (TTM) | €267.85m |
| Revenue (TTM) | €1.57b |
17.0x
P/E Ratio2.9x
P/S RatioIs LP6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LP6 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.86b |
| Cost of Revenue | CN¥4.39b |
| Gross Profit | CN¥7.46b |
| Other Expenses | CN¥5.44b |
| Earnings | CN¥2.02b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | 2.23 |
| Gross Margin | 62.94% |
| Net Profit Margin | 17.08% |
| Debt/Equity Ratio | 27.4% |
How did LP6 perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yield62%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 20:19 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Livzon Pharmaceutical Group Inc. is covered by 28 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Helena Qiu | CCB International Securities Limited |
| Shuchang Liu | Changjiang Securities Co. LTD. |